A Seeking Alpha contributor expects the Food and Drug Administration to approve MannKind's (Nasdaq: MNKD) inhalable insulin product Afrezza. Shares of the biopharmaceutical gained 37 cents to close at $7.39.
Seeking Alpha expects FDA approval for MannKind
May 19, 2014 at 17:09 PM EDT
